The Australia and New Zealand Clinical Quality Registry for the Treatment of Eating Disorders (TrEAT Registry) supports clinical outcomes monitoring and reporting for people receiving eating disorders treatment. Participating services including private and public outpatient, day program, and residential eating disorder treatment centres in Australia and New Zealand. Clients at these services complete patient reported outcome measures before and throughout treatment. A feedback mechanism is employed whereby summaries of scores with norming data are sent immediately to clinicians to guide clinical decision-making. Service-wide reports are generated and benchmarked against the pooled registry data across services. Researchers use the registry to answer questions about eating disorder phenomenology and treatment. The TrEAT Registry captures clients aged 13 years and older, and all participating clients/caregivers provide informed consent for the use of their data to be included in the database for auditing and research purposes.

The objective of the registry is to provide a platform for participating sites to enter data to measure post-operative quality of recovery after a surgical procedure. These data will be used to answer multiple research questions in the future, as well as to provide benchmarking data for recovery for specific operations. Specific research questions that will utilise the registry data will require separate HREC approval. The primary outcome measure tool is the Postoperative Quality of Recovery Scale (PostopQRS).

The Tasmanian Emergency Care Outcomes Registry is a clinical quality registry (self-reported) that aims to monitor the quality of clinical care provided by Tasmanian Emergency Departments. The primary objective for determining the quality of clinical care is by measuring 30-day mortality and safety event data (morbidity).

The Australasian Registry of Electrocardiograms in National Athletes (ARENA) is a clinical quality registry (self-reported). ARENA collects cardiac screening data for athletes over the age of 16 years, including ECGs and results of other cardiac tests from sporting organisations in Australia and New Zealand. It is led by researchers at the University of Sydney, in collaboration with other national and international experts, and based at the South Australian Health and Medical Research Institute (SAHMRI) Registry Centre. ARENA was launched in 2023, initially in Australia, with New Zealand to follow as funding allows. All sporting organisations conducting cardiac screening of athletes (including ECG) are eligible to provide data. Outcomes and diagnoses will be monitored regularly. 

ARENA will provide a long-term international data repository to improve our understanding of ECG interpretation, cardiac screening and diagnoses, and the rates of major cardiac events in screened athletes. A unique aim is to address important evidence gaps in under-represented athlete groups, specifically female athletes and Indigenous populations. Results will inform policy and guidelines. The overall aim is to improve the quality of their cardiac screening programs and provide better cardiac care for young athletes.

LUCAP is a clinical quality registry (self-reported) for lung cancer care in Australia. The platform enables the performance of continuous audit cycles against endorsed key clinical quality indicators (CQI) of care to identify where significant improvements can be made to deliver consistent, world-class care. The type of information LUCAP collects includes: 

• how quickly people get tests
• what sort of tests are performed
• how quickly people get treatments. 

Ultimately, LUCAP aims to improve the quality of care and outcomes for lung cancer patients in Australia by developing a culture of accountability and responsibility in institutions that treat lung cancer in Australia. 

The key objectives of LUCAP are to: 

• Implement a standardised and high quality data collection process across all jurisdictions in Australia
• Enable the generation of risk-adjusted reports on the quality of lung cancer care across Australia for consumers, healthcare providers and researchers, and provide close-to real time dashboards to facilitate clinical and quality improvement initiatives
• Enable the generation of high-quality research data for observational and/or registry-based studies, facilitating and enhancing novel research and new treatment approaches for lung cancer patients. 

LUCAP is currently being implemented in the hospitals listed below, with the intention to expand to all hospitals across Australia (and New Zealand) in the future. LUCAP is supported by Cancer Australia and the peak lung health body the Lung Foundation Australia (LFA). The LUCAP Protocol is endorsed by the Thoracic Society of Australia and New Zealand (TSANZ).

The purpose of the Registry is the collection of outcome and safety data on the use of transcranial magnetic stimulation (TMS) and other brain stimulation techniques. The Registry will include any patients receiving TMS who are referred by their treating physician and consent to participate in data collection. The Registry will expand to include other brain stimulation techniques in the future. The outcomes measured will depend on their diagnosis. 

The Australian Diabetes Foot Registry standardises data collection in High Risk Foot Services (HRFS) nationally, providing an unprecedented opportunity for audit, benchmarking, quality improvement and collaborative research. HRFS deliver specialist interdisciplinary care to people with diabetes-related foot complications, including ulceration, osteomyelitis and Charcot foot. These services are established to reduce the healthcare and individual burden of diabetes-related foot complications by coordinating care, reducing hospitalisation and improving clinical outcomes. However, prior to establishment of the ADFR, siloed and often insufficient data collection practices impeded comprehensive outcome evaluation. With introduction of a national HRFS Standards and Accreditation program by the National Association of Diabetes Centres, the need for national data collection, centralised support and infrastructure to meet quality improvement standards was recognised. The primary objective of the ADFR is to develop a standardised Australian diabetes repository for HRFS. Secondary objectives are to evaluate service and clinical outcomes, perform national benchmarking, provide reports to participating services, and establish a platform for local and collaborative research. Data is prospectively and longitudinally collected on people with diabetes and one or more active foot complications attending a participating HRFS. The project has ethics approval under the National Mutual Acceptance Scheme with an opt-out consent approach (waiver of consent in WA and NT). Data and outcome domains span participant demographics, diabetes characteristics, comorbidities, ulceration characteristics and classification, Charcot foot characteristics and classification, referral processes, telehealth utilisation, interdisciplinary involvement, offloading practices, antibiotic prescription, hospitalisations, surgical interventions including amputation, service wait times, remission and recurrence of complications, and service separation.

The purpose of the AIPPAP Research Registry is the collection of outcome and safety data on the use of novel interventional pharmacotherapy approaches, including ketamine treatment and psychedelic-assisted psychotherapy for mental health disorders. The AIPPAP Research Registry will include any patients receiving MDMA, psilocybin, or ketamine who are referred by their treating physician and consent to participate in data collection. The outcomes measured will depend on their diagnosis.